Loading…
← CockpitCompetitor Analysis › OMER Omeros CorporationOpen in the cockpit ↗

Omeros CorporationOMERCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech developing complement-pathway inhibitors (narsoplimab) for rare blood and transplant-related diseases.

Momentum neutral 47
Mkt cap
$1.08B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$21.8M
20-day average traded
Fwd P/E
4.3×
forward earnings
ROIC−WACC
-47.0 pp
WACC 16.8%
Hurdle
n/a
no reverse DCF
Next earnings
138 days
5 Apr 2027
Close · USD$14.55
1D+4.5%
1W-19.8%
1M-12.1%
3M-21.9%
6M+24.4%
YTD-15.3%
1Y+131.7%
ATR %7.5%
Beta1.40
52w lowhigh31.5% off high

What Omeros does

Biotech developing complement-pathway inhibitors (narsoplimab) for rare blood and transplant-related diseases.

Has no product of its own on sale after selling its Omidria eye-surgery drug in 2021, so it funds development from capital it raises and from deals tied to that sale. Revenue from narsoplimab would start only if regulators approve it.

Products and services

  • Narsoplimab (TA-TMA)
  • Complement pipeline

Where it sits in the supply chain

  • Biopharma R&D
  • Complement (MASP-2) pathway inhibitors
  • Rare hematology/transplant disease…

What could go right

  • Narsoplimab approval for TA-TMA
  • New complement pipeline data

What could go wrong

  • Past FDA rejection/complete response letter
  • Cash runway/dilution risk

Moat: narrow (IP / patents). MASP-2-targeted mechanism is differentiated from complement C5 inhibitors used by rivals.

Headquarters: Seattle, Washington, US · Founded: 1994 · Employees: 175

Named competitors

Omeros at a glance

Size Omeros (OMER) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.08B, the 2178th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.55 on 18 Nov 2026.

Performance Over six months the shares gained 24.4%, against -9.7% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth The operating margin is -56.4% (peer median 8.9%).

Valuation It trades at 4.3× forward earnings against a peer median of 18.2× (cheapest of 15).

Capital Return on invested capital runs 47.0 points below its cost of capital (16.8% WACC).

Short interest Short interest is 17.7% of the free float (30 Oct 2026).

Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026OMER 122Peer median 93
Six months, rebased to 100: Omeros against the median of its 20 peers (local-currency closes).

Omeros financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$74.4M$0$0$0$0
Revenue growth—————
Gross profit$71.3M-$964,000-$950,000-$920,000-$952,000
EBITDA-$41.1M-$122M-$168M-$164M-$162M
Net income$98.4M-$3.35M-$157M-$118M$47.4M
Free cash flow-$43.4M-$123M-$149M$74.3M-$86.6M
Capital expenditure$70,000$65,000$165,000$426,000$113,000
Total debt$295M$407M$423M$362M$468M

Quarterly statements and history in the cockpit →

Omeros competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%600812MEDCLPYCVETO300119237690VIYASH1952006280BLUEJET600789BSLNCMHC0027374547688513OMER6-month return →1-month return →
Up and to the right = strong over both horizons. Omeros is the large dot.

Omeros competitors and peer comparison

Head to head with its named competitors (OMER vs AZN.L vs SAN.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Omeros OMER$1.08B+24%n/a-56%4.3×n/a
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%

How Omeros compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Omeros against its 20 peers (data as of 18 Nov 2026)
MeasureOMERPeer medianRank in peer set
1-month return-12.1%-1.1%5th lowest of 21
6-month return+24.4%-9.7%3rd highest of 20
Distance from 52-week high-31.5%-26.8%10th lowest of 21
Operating margin-56.4%8.9%2nd lowest of 18
Forward P/E4.3×18.2×cheapest of 15
ROIC minus cost of capital-47.0 pp-0.2 pplowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%27.8×4.2%+21.7%
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%32.2×36.3%+20.4%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%4.6×n/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%418.7×n/an/a
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%18.4×3.4%-1.2%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%

Questions

Who are Omeros's main competitors?
Named competitors: AstraZeneca (Alexion) (AZN.L), Apellis Pharmaceuticals (private or unlisted), Sanofi (SAN.PA). The cockpit's measured peer set (industry) also includes North China Pharmaceutical (600812.SS), MedinCell (MEDCL.PA), PYC Therapeutics (PYC.AX), Vetoquinol (VETO.PA), Tianjin Ringpu Bio-technology (300119.SZ), ST Pharm (237690.KS).
Is Omeros expensive compared with its peers?
On forward p/e it trades at 4.3× against a peer median of 18.2×, cheapest of 15 in its peer set.
How has Omeros stock performed?
Over six months to 18 Nov 2026 the shares returned +24.4% against -9.7% for the median peer; over one year +131.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.